The overall goal of the project is to develop CAR T cell therapy for treating children with brain tumours and recurrent, refractory, or metastatic bone tumours. The efficacy of EphA2 CAR T cells will be tested by in vitro cytotoxicity assays, 3D tumour culture models and tumour bearing mouse models for osteosarcoma, ewing’s sarcoma and brain tumours, including orthotopic mouse xenografts of patient derived DIPGs and other tumour types. The project also aims to design novel CAR constructs to address the specific challenges facing solid tumour targeted CAR T cell therapy as a basis for improving efficacy, safety and by broadening potential targets in the context of paediatric cancers
Started: 1 January 2018
Ending: 31 December 2019
